AMRX Stock Hub: Amneal News, Kashiv Integration and Cash Flow

AMRX stock at a glance

Where Amneal Pharmaceuticals stands now

Q3 net revenue was $862.684 million, up 10% year over year. Affordable Medicines contributed $547.109 million, Specialty $150.262 million and AvKARE $165.313 million. The first two segments grew 19% and 20%, while AvKARE declined 17% against a non-recurring prior-year cardiovascular launch. Company disclosure.

Consolidated GAAP net income was $12.306 million. Deducting $19.762 million non-controlling income gives a $7.456 million attributable loss before $14.239 million redeemable-NCI accretion; the final loss attributable to Amneal was $21.695 million, or $0.06 per diluted share. Company adjusted EBITDA was $207.029 million and adjusted net income $89.505 million, or $0.26 per adjusted diluted share. Company disclosure.

Nine-month CFO was $50.312 million; Q3 CFO was $98.299 million, calculated as nine months less the first-half outflow. September cash was $157.399 million and restricted cash $22.854 million separately. Gross debt was $3,230.747 million, net debt $3,073.348 million and company net leverage 3.9×. The $16.484 million rupee facility included at September 30 was repaid October 1. Company disclosure.

Latest Amneal Pharmaceuticals news

AMRX stock catalysts: cash collection, launches and integration

• November 3, 2026 — Q3 results and cash-flow forecast revision reported; call complete. Completed
• Q4 2026 — Cash collection, inventory, launch contribution and Kashiv integration under the revised annual forecast. Operating watchpoints
• 2026 / 2027 roadmap — Denosumab/device and omalizumab launch plans have dated company windows, separate from newly announced FDA target days. Development and launch estimates
• April 2027 — CREXONT/Sandoz patent trial scheduled in the August 10-Q. Dated court schedule; may change
• 2028–2030+ — Kashiv advanced and earlier biosimilar candidates. Strategic development goals
• Date not announced — Next earnings, tirzepatide approval and Brookhaven operating start. No fixed dates

Latest results and current guidance · Dated legal and development disclosures

AMRX revenue growth and the cash-conversion test

The issuer’s EBITDA adds net interest, tax and D&A to consolidated net income, producing $127.229 million in Q3; $79.800 million net adjustments then give $207.029 million adjusted EBITDA. It includes 100% of AvKARE EBITDA, while adjusted EPS accounts for non-controlling interests. Acquisition/site costs, impairment, SBC, refinancing and TRA changes have different recurrence and cash effects. Company disclosure.

Nine-month PP&E purchases were $70.659 million and future-equipment deposits $28.376 million. CFO less PP&E was calculated negative $20.347 million, or negative $48.723 million including those deposits, before intangible purchases and acquisitions. Q3 CFO less PP&E was positive $66.512 million, or $58.716 million including deposits. Period and investment definitions matter. Company disclosure.

Receivables used $122.423 million, inventory $158.346 million and prepaids/other assets $113.073 million over nine months. The updated cash guidance implies $274.688–324.688 million Q4 CFO. That is a calculation from the annual plan, rather than a separate company quarterly forecast. Company disclosure.

AMRX launches, Kashiv obligations and the forward evidence

The Q3 release identifies lanreotide among growth drivers but provides no standalone revenue or margin. The September 18 approval and September 21 first marketing date are separate from the $983 million historical reference-brand market. CREXONT, BREKIYA and UNITHROID support Specialty, while RYTARY’s expected decline affects the net mix. Company disclosure. FDA approval and first-marketing record. Q2 brand-mix discussion.

Kashiv acquisition cash outflow was $421.047 million net of acquired cash/restricted cash over nine months. Related-party contingent consideration carrying liabilities were $59 million current and $324 million noncurrent, separate from gross financial debt and from the original maximum regulatory milestones. Company acquisition/integration expense was $35.073 million over nine months. Company disclosure.

Generic tirzepatide ANDAs were accepted for review July 8; acceptance is separate from approval or a dated launch. The April 2027 CREXONT/Sandoz trial date is disclosed in the August filing, while litigation schedules may change. Biosimilar roadmap windows carry their original dates until a new regulatory or launch event is announced. Company disclosure.

Merlintrader Health Score · $AMRX

Reassessed November 4, 2026. Weighted calculation: 2.0×30% + 3.5×30% + 2.5×20% + 3.5×10% + 3.5×10% = 2.85 / 5. Financial and operational robustness over twelve to eighteen months; not an investment recommendation or clinical-success probability.

Red flags

• Gross debt of $3,230.747 million is substantial relative to $157.399 million unrestricted cash. Net leverage uses the company’s adjusted EBITDA definition.
• The revised annual cash forecast requires calculated $274.688–324.688 million Q4 CFO after only $50.312 million over nine months.
• Consolidated net income, loss attributable to Amneal, adjusted net income and EBITDA have different definitions and shareholder scopes.
• Kashiv adds issued shares, contingent consideration, debt and integration requirements. A resale registration is separate from new issuance or actual sales.
• Lanreotide approval and launch do not guarantee price, market share or cash collection. Tirzepatide acceptance is separate from FDA approval.
• Manufacturing damage, supply interruptions and legal obligations remain risks. The Q3 footnote’s government-investigation charge is an accounting disclosure, separate from a legal outcome.